PFK-158 FREE BASE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H11F3N2O
Molecular Weight	328.2879
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)C1=CC2=C(C=CC(\C=C\C(=O)C3=CC=NC=C3)=N2)C=C1

InChI

InChIKey=IAJOMYABKVAZCN-AATRIKPKSA-N

InChI=1S/C18H11F3N2O/c19-18(20,21)14-3-1-12-2-4-15(23-16(12)11-14)5-6-17(24)13-7-9-22-10-8-13/h1-11H/b6-5+

HIDE SMILES / InChI

Molecular Formula	C18H11F3N2O
Molecular Weight	328.2879
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 1 Target ID: CHEMBL2331053 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072985/pdf/2049-3002-2-S1-P14.pdf \| https://cancerres.aacrjournals.org/content/75/15_Supplement/CT206?cited-by=yes&legid=canres;75/15_Supplement/CT206	Inhibitor 8297

PubMed

Title	Date	PubMed
Synergistic Effect of Colistin Combined with PFK-158 against Colistin-Resistant Enterobacteriaceae.	2019 Jul	30988150

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:55:25 GMT 2023` Edited by `admin` on `Sat Dec 16 10:55:25 GMT 2023`
Record UNII	2HOK1JQ203
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PFK-158 FREE BASE

Code

English

2-PROPEN-1-ONE, 1-(4-PYRIDINYL)-3-(7-(TRIFLUOROMETHYL)-2-QUINOLINYL)-, (2E)-

Systematic Name

English

Code System Code Type Description

FDA UNII

2HOK1JQ203

Created by admin on Sat Dec 16 10:55:25 GMT 2023 , Edited by admin on Sat Dec 16 10:55:25 GMT 2023

PRIMARY

MANUFACTURER PRODUCT INFORMATION

PFK-158 FREE BASE

Created by admin on Sat Dec 16 10:55:25 GMT 2023 , Edited by admin on Sat Dec 16 10:55:25 GMT 2023

PRIMARY

MedKoo CAT NO.: 206166, CAS NO.: 1462249-75-7Description: PFK-158, also known as ACT-PFK-158, is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFK-2/FBPase) isoform 3 (PFKFB3) with potential antineoplastic activity. Upon administration, PFKFB3 inhibitor PFK-158 binds to and inhibits the activity of PFKFB3, which leads to the inhibition of both the glycolytic pathway in and glucose uptake by cancer cells. This prevents the production of macromolecules and energy that causes the enhanced cellular proliferation in cancer cells as compared to that of normal, healthy cells. Depriving cancer cells of nutrients and energy leads to the inhibition of cancer cell growth. (Last updated: 3/22/2016)Synonym: PFK158, PFK 158, PFK158, ACTPEK158.

CAS

1462249-75-7

Created by admin on Sat Dec 16 10:55:25 GMT 2023 , Edited by admin on Sat Dec 16 10:55:25 GMT 2023

PRIMARY

PUBCHEM

71730058

Created by admin on Sat Dec 16 10:55:25 GMT 2023 , Edited by admin on Sat Dec 16 10:55:25 GMT 2023

PRIMARY

Related Record Type Details


					2HOK1JQ203

PFK-158 FREE BASE

ACTIVE MOIETY

Comments:

Originator: University of Louisville; Developer: Advanced Cancer Therapeutics; Class: Antineoplastic, Small molecule; Mechanism of Action: Glucose modulator, PFKFB3 protein inhibitor Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Solid tumours; Most Recent Events: 01 Mar 2014 Phase-I clinical trials in Solid tumours in USA (IV) (NCT02044861), 22 Jan 2014 Preclinical trials in Solid tumours in USA (IV), 22 Jan 2014 Advanced Cancer Therapeutics plans a phase I trial for Solid tumours (second-line therapy or greater, late-stage disease) in USA (NCT02044861)